Anavex Life Sciences Corp (AVXL)

[JB3729]

If 3 71 is better, why are they wasting time on furthering trials on 2 73?

Nobody will know which drug is better until they both complete trials. One may work better for some diseases while the other works better on other diseases.

Anavex had to develop A2-73 or risk losing their rights to it -

Anavex (like most cash-strapped early-stage biotech companies) was not in good financial shape following the 2008 recession and may have been on the verge of failing to meet the obligations set forth in their agreement - and therefore on the verge of loosing all rights related to the patents. In the 2012 addendum, paragraph 2.1 is replaced with:

Assignee shall have invested, by December 31, 2017, at least $1,000,000 in the development and patenting of the subject matter of Article I, paragraph 1.1. For clarity the "development and patenting of the subject matter of Article I, paragraph 1.1" shall be termed the "Project"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121027856